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Many cancers harbor homozygous DNAdeletions (HDs). In contrast
to other attributes of cancer cells, their HDs are immutable features
that cannot change during tumor progression or therapy. I describe
an approach, termed deletion-specific targeting (DST), that em-
ploys HDs (not their effects on RNA/protein circuits, but deletions
themselves) as the targets of cancer therapy. The DST strategy
brings together both existing and new methodologies, including
the ubiquitin fusion technique, the split-ubiquitin assay, zinc-
finger DNA-recognizing proteins and split restriction nucleases.
The DST strategy also employs a feedbackmechanism that receives
input from a circuit operating as a Boolean OR gate and involves
the activation of split nucleases, which destroy DST vector in
normal (nontarget) cells. The logic of DST makes possible an
incremental and essentially unlimited increase in the selectivity of
therapy. If DST strategy can be implemented in a clinical setting, it
may prove to be curative and substantially free of side effects.
split nucleases  split ubiquitin  zinc fingers
A major obstacle to drug-based therapies of human diseases thatare both efficacious and substantially free of side effects is the
massive interconnectedness and redundancy ofmolecular circuits in
living cells. In the case of cancer, the problem is exacerbated by
genomic instability of many, possibly most, cancers. This property
increases heterogeneity of malignant cells in the course of tumor
progression or anticancer treatment and is one reason for the failure
of most drug-based cancer therapies (1, 2). A few relatively rare
cancers, such as testicular carcinoma, Wilm’s kidney tumor, and
some leukemias in children, can often be cured through chemo-
therapy but require cytotoxic treatments of a kind that cause severe
side effects and are themselves carcinogenic (3, 4). Several recent
advances, including the use of antiangiogenic compounds and
inhibitors of specific kinases, hold the promise of efficacious,
curative therapies (5–7). Nevertheless, major human cancers are
still incurable once they have metastasized.
In the present work, I suggest an approach to cancer therapy that
involves homozygous deletions (HDs). Recent studies have dem-
onstrated that many human cancers, including major ones, contain
a significant number of scattered homozygous deletions (8–21). A
salient property of anHD that involvesDNA sequences not present
elsewhere in the genome is that HD cannot revert. For this and
other reasons, HDs may prove to be a particularly appropriate
target for therapy. The difficulty here is that HD is an ‘‘absence,’’
and therefore it cannot be a conventional molecular target. Nev-
ertheless, an HD-specific anticancer regimen is feasible through a
strategy described below (Figs. 1–3).
This strategy, termed deletion-specific targeting (DST), employs
homozygous deletions as ‘‘negative’’ targets of cancer therapy. The
DST strategy is implemented through molecular circuits that com-
bine both existing and new methodologies. One of the methods is
the ubiquitin (Ub) fusion technique (22, 23). In addition, an
essential part of DST strategy is based on “helper-dependent”
split-protein devices, introduced by Johnsson and Varshavsky (24)
in 1994 with the split-Ub assay and thereafter extended to other
split-protein constructs, including dihydrofolate reductase (DHFR)
(25), GFP (26–28), and -lactamase (29, 30). Split-protein domains
coupled toDNA-recognizing proteins (31) are also a component of
DST strategy. Yet another part of DST is a conditional destruction
of DST vectors by (reconstituted) split-restriction nucleases and a
time delay in activating a vector’s payload (Figs. 1–3). A major
advantage of DST is its essentially unlimited selectivity. As de-
scribed below, the logic and scope ofDST is relevant to applications
beyond HDs, as well as outside of cancer.
Homozygous DNA Deletions in Many, Possibly Most, Cancers. Germ-
line DNA of phenotypically normal humans has been shown to
contain, on average, 30 hemizygous deletions larger than 5 kb,
with regions of hemizygocity owing to deletions encompassing
550 kb altogether (0.02% of the genome) (32, 33). Given the
rarity of these hemizygous deletions, the bulk of homozygous
deletions observed in cancer cells are de novo ones, acquired during
tumor initiation and/or progression. Cancer-associated deletions
that are relevant to the DST strategy are exclusively those that are
at least partially homozygous and involve unique nucleotide se-
quences (Fig. 1). Although a hemizygously deleted DNA can be
phenotypically similar to a homozygous deletion, owing, for exam-
ple, to methylation of the region’s remaining copy (34), only HDs
are relevant to the DST strategy. Besides their advantage of zero
reversion frequency, an HD is also a ‘‘digital’’ entity, in that the
absence versus presence of a DNA sequence enables more robust
designs that use deletions as targets.
Recent methods for detecting copy number changes in large
genomes added a number of cancer-associated homozygous dele-
tions to relatively few HDs that were unambiguously identified in
earlier studies. Many cancers harbor HDs at fragile sites, defined
(outside the context of cancer) as chromosomal regions that stain
weakly in mitotic chromosome spreads of cells subjected to stress
during DNA replication. For example, human cell lines derived
from carcinomas of the stomach, lung, breast, ovary and colon often
contain HDs, of a few to 200 kb in size at one or both of the two
fragile sites called FRA3B and FRA16D (ref. 8 and references
therein). Many other homozygous deletions were also identified in
various cancers and in cell lines derived from them. These HDs
encompass specific tumor suppressor genes such as, for example,
SMARCB1/INI1 or PTEN, and other regions that are either known
or suspected to contain tumor suppressors (9–20). One example is
a study of multiple myeloma, a cancer originating from B-
lymphocytes. Myeloma cells were shown to exhibit a broad range of
copy-number changes in specific DNA regions, including multiple
HDs whose sizes varied from 20 kb to 11 Mb (21). Whereas some
deletions were observed in several myeloma patients, other HDs
were apparently patient-specific (21). This pattern, which recurs in
other cancers as well, suggests that some HDs are under positive
selection in an evolving tumor, whereas other HDs of the same
Author contributions: A.V. designed research, performed research, analyzed data, and
wrote the paper.
The author declares no conflict of interest.
Abbreviations: DST, deletion-specific targeting; HD, homozygous deletion; Ub, ubiquitin;
ZF, zinc finger; ZFN, ZF nuclease.
*E-mail: avarsh@caltech.edu.
© 2007 by The National Academy of Sciences of the USA
www.pnas.orgcgidoi10.1073pnas.0706546104 PNAS  September 18, 2007  vol. 104  no. 38  14935–14940
BI
O
CH
EM
IS
TR
Y
cancer, in the same patient, may be quasineutral, randomly retained
deletions.
DST and Its Implementation. Employing homozygous deletions, not
their effects on tumor suppression and RNA/protein circuits but
deletions themselves, as a target of therapy is, to my knowledge, a
previously undescribed idea. Although the number of known
cancer-associated HDs is already large, their current set is still the
tip of the iceberg. In other words, future mapping studies would be
likely to find that specific cancers in individual patients can be
(nearly) always relied on to contain at least two homozygous
deletions that satisfy the constraints of DST (Fig. 1). The DST
strategy is independent, to a striking extent, of considerations that
underlie other approaches to cancer therapy. For example, DST
does not involve a function of deleted DNA, or its levels of
expression in normal cells, or tumorigenic alterations of RNA/
protein circuits in cancer cells, or cell-surface differences between
them and normal cells.
Two HDs that are chosen for therapy are the sole selectivity
determinants of DST strategy. The operation of the DST circuit,
including the final stage at which the ‘‘decision’’ is made to either
destroy a DST vector (if it entered a normal cell) or to allow the
activation of a vector’s payload (e.g., a cytotoxic protein) is de-
scribed, step by step, in DST Circuit and Its Operation. Given the
logic of DST (Figs. 1–3), a third and even fourth HD can be added
as concurrent targets. Because the negative ‘‘spare this cell’’ output
of a DST circuit is a part of its operation as a Boolean OR gate, an
incremental addition of HDs as targets would increase the selec-
tivity of treatment exponentially rather than linearly. The challenge,
then, is to design a circuit that can sense, in effect, a DNA-dosage
difference simultaneously for two (ormore) loci at an error rate that
can bemade arbitrarily small. In a ‘‘complete’’ DSTdrug, aBoolean
output of such a circuit is used to either irreversibly destroy a DST
vector, thereby precluding activation of its payload, or to activate
the payload if the circuit reports the presence of both HDs in a cell
(Figs. 1–3). In a clinically relevantDST strategy, aDNA-basedDST
vector would be (nonspecifically) delivered into cells of a patient by
using, for example, nonreplicating viruses or liposome-encapsu-
lated DNA.
At this stage, the nearest aim is not a clinically realistic DST
design but rather the circuit’s ability to function as a DST device.
Given the focus of DST on targets that cannot be altered in the
course of tumor progression, a relevant design must be sensitive to
HDs themselves, i.e., to the absence of specific DNA sequences. In
other words, a DST device should not target, for example, a
junctional DNA sequence at a deletion’s breakpoint, because the
latter, although unique to target cells, is not immune to change, in
contrast to HD itself. Another desirable specification of a DST
circuit is modularity, including the feasibility of increasing the
circuit’s selectivity by adding modules similar to those already
present. These andother considerations led to a specificDSTdesign
whose components and operation are described in Fig. 2 and
summarized in Fig. 3.
DST Circuit and Its Operation. Fig. 1B depicts a pair of overlapping
hemizygous deletions, 11 and 12. A segment of removed DNA in
common between these deletions is termed DNA-1, and the
corresponding homozygous deletion is termed HD1. 21 and 22
are another pair of hemizygous deletions. In Fig. 1B, they are
located on a different pair of chromosomes, but they can also be
located on the same pair of chromosomes as the first set of
hemizygous deletions. DNA-2 is the segment of removed DNA in
common between 21 and 22, and the corresponding (second)
homozygous deletion is termed HD2 (Fig. 1B). What follows is a
brief description of DST constructs and the circuit they comprise
(Figs. 2 and 3).
1. As discussed above (Fig. 1), one identifies at least two homozy-
gous deletions, termedHD1 andHD2, in a population of target
cells. These deletions removed DNA segments termed DNA-1
and DNA-2. Although HD1 and HD2 should encompass
uniqueDNAsequences, theirminimally acceptable sizes can be
as small as 100 bp (see item 6).
2. One ‘‘half’’ of DST circuit is implemented by two ‘‘comple-
mentary’’ protein fusions termed DST-f1 and DST-f2 (Fig. 2 A
andB). The other, mechanistically identical ‘‘half’’ of the circuit
is implemented by fusions termedDST-f3 andDST-f4 (Fig. 2G;
Fig. 1. DST. (A) Chromosome pairs 1 and 2 (arbitrarily numbered) in a diploid cell. (B) The same chromosomes in a cell that contains two HDs, termed HD1 and
HD2. Each of two HDs results from overlapping hemizygous deletions 11 and 12 in chromosome 1 and 21 and 22 in chromosome 2. The nonoverlapping parts
of hemizygous deletions are in purple. Their overlapping parts, which comprise, respectively, HD1 and HD2, are in red on chromosome 1 and in green on
chromosome 2. In Figs. 2 and 3 and in the main text, the segments of DNA that had been removed fromwild-type cells as a result of homozygous deletions HD1
and HD2 are called, respectively, DNA-1 and DNA-2. (C) Outline of DST.
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see items 6 and 10). The fusionDST-f1 (Fig. 2A) consists of the
following domains, beginning at its N terminus.
3. The first domain ofDST-f1 (Fig. 2A) is anN-terminal fragment
of a restriction endonuclease (restrictase-1, or r1) whose spe-
cific DNA cleavage site is absent from human DNA but is
present, at multiple locations, in the DNA of the DST vector
(Fig. 2C). Similarly to the previously characterized “helper-
dependent” split proteins (see Introduction), the split restric-
tase r1 is constructed in such a way that a moderate-level
coexpression of its N-terminal and C-terminal fragments (Fig.
2 A and B) cannot reconstitute the enzymatically active r1
restrictase, but it can be reconstituted if these fragments are
Fig. 2. DSTdevices and their implementation. SeeDSTCircuit and ItsOperation for descriptions of specific components and circuits shown. (A) DST-fusion-1 (DST-f1).
(B) DST-f2 fusion. (C) The ORFs of DST vector, which contains at least five ORFs. The ORF(s) encoding ‘‘payload’’ P (e.g., a conditionally toxic protein) is in yellow. See
item 11 in themain text for a description of payload’s design and induction. (D) DST vector enters normal (nontarget) cells, which contain either one or both of DNA
segments,DNA-1andDNA-2, thatareabsent in target cells, owing to thehomozygousdeletionsHD1andHD2.OnlyDNA-1and its ligandsDST-f1andDST-f2are shown
inD. The other pair of DST fusions, which recognize DNA-2, is shown inG. (E) The operation of DST circuit in a normal (nontarget) cell, which is depicted, without loss
of generality, to contain both DNA-1 and DNA-2. It may also contain just one of two DNA segments. DUB, deubiquitylating enzyme; UBLP, Ubl-specific protease. (F)
ConditionaldestructionofDSTvector.Thereleasedr1nucleasebecomesfreetotarget its cleavagesites inDSTvector,digesting it tosmall fragmentsandtherebyhalting
the expression of its ORFs, including the (possibility of) expression of vector’s payload P. Note that payload’s expression had not been induced as yet at this stage. (G)
If bothDNA-1andDNA-2arepresent inanon-target cell, as shownhere, anotherwise identical liberationof the reconstitutednuclease r2 takesplaceaswell. (H) Events
inatargetcell, i.e., theonethatcontainsbothHD-1andHD-2,andhadreceivedDSTvector.BecauseneitherDNA-1norDNA-2arepresent insuchcells, thereconstitution
of r1or r2 (which require thebindingof ZFdomains toDNA-1orDNA-2) does not takeplace, and theDST vector stays intact. After anempirically optimized timedelay,
to allow DST circuits to search for DNA-1 and/or DNA-2, the vector’s payload P (e.g., a cytotoxic protein) can be activated.
Fig. 3. Summary ofDST strategy and its logic. (A) DST in normal (nontarget) cells, which contain either bothDNA-1 andDNA-2 segments or at least one of them.
All of such cells are spared, given the logic of DST circuits described here, in the legend to Fig. 2, and in the main text. (B) DST in target cells, lacking both DNA-1
and DNA-2 segments.
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brought into spatial proximity in vivo, as shown in Fig. 2E. One
example of a site-specific endonuclease with requisite cleavage
specificity is yeast SceI, which cuts DNA at an 18-bp-long
recognition site (35). SceI is a member of the large and
extensively characterized class of ‘‘homing’’ endonucleases,
which mediate, in particular, the activity of selfish genetic
elements (reviewed in ref. 36). Another class of site-specific
endonucleases that can also be used to design a split restrictase
includes artificial (engineered) ZF nucleases (ZFNs) (37–41).
Although no split versions of restriction nucleases were de-
scribed so far, extensive studies with other split-protein designs
over the last decade (refs. 24–30 and references therein) suggest
that a split restriction nuclease with required properties is
feasible.
4. The next domain of DST-f1 (Fig. 2A) is Cub, a C-terminal half
of the 76-residue Ub moiety and a part of the previously
characterized split-Ub sensor (24).
5. The third domain of DST-f1 is a mutated N-terminal half of a
Ub-like (Ubl) protein, for example NEDD8 or SUMO (42),
that is a part of the additional (Ubl-based) split-protein sensor
in the current DST design. Linking split-Ub and split-Ubl in the
same pair of fusions (Fig. 2 A and B) makes possible a
conditional cleavage of two polypeptide chains at once (after
the last residue ofUb inDST-f1 and after the last residue ofUbl
in DST-f2) and the resulting release of (reconstituted) restric-
tase r1, as shown in Fig. 2 E and F. A properly placed and
double (as distinguished from single) proteolytic cleavage may
be essential: a single cleavage would not release the reconsti-
tuted (previously split) restrictase r1 moiety, because the Ub
halves and the Ubl halves of DST-f1/DST-f2 remain associated
at this stage. No split versions of Ubl proteins were described
so far. However, because all Ub-like proteins share the central
feature of the Ub fold (a short -helix over a -fold), and
becauseUb fold-destabilizingmutations (in theN-terminal half
of Ub) were previously characterized with the split-Ub sensor
(24), it is nearly certain that a split Ubl protein with required
properties is feasible. Technical note: it is possible (but remains
to be verified) that a simpler design is feasible as well. A split
Ubl moiety (instead of the second split-Ub moiety) was envi-
sioned in DST-f1/DST-f2 fusions (Fig. 2 A and B) to bypass the
problem of intramolecular (as distinguished from intermolec-
ular) reconstitution of theUbmoiety. In other words, if the Cub
half of Ub is followed, in DST-f1, by the Nub half of Ub, the two
halves may be able to associate intramolecularly, an event to
avoid: hence the use of split Ubl, which would be designed to
be incapable of cross-associating with split Ub. However, if the
linker sequences involved are made sufficiently short, steric
constraints may prevent intramolecular folding and the (unde-
sirable) reconstitution of theUbmoiety. If so, itmay be possible
to construct DST-f1/DST-f2 fusions with two otherwise iden-
tical split-Ub moieties oriented in opposite directions, instead
of split-Ub and split-Ubl.Whether this simpler design is feasible
remains to be determined.
6. The fourth and last domain of DST-f1 is ZF1–1, a ZF protein
domain, similar to the previously described and extensively
characterized ZF proteins that recognize specific DNA se-
quences (43–46). The ZF domains ZF1–1 and ZF1–2, of the
fusions DST-f1 and DST-f2, respectively (Fig. 2 A and B), are
designed to bind to two adjacent 9 bp (if necessary, longer)
sequences of DNA-1 (Fig. 2D). The two ZF-binding sequences
ofDNA-1 are spaced apart to position their binding surfaces on
the same side of the DNA double helix. Coexpression of
DST-f1 and DST-f2, and the binding of ZF1–1 and ZF1–2 to
the above two sequences of DNA-1 would bring the rest of
DST-f1 and DST-f2 fusions into close proximity, thereby
inducing reconstitution of the split restrictase r1, of Ub, and of
Ubl, as shown in Fig. 2D–F. This reassembly leads to cleavages
by constitutively present deubiquitylating (DUB) enzymes after
the last residue of Cub (24) and by (also constitutively present)
Ubl-specific proteases (UBlPs) (42) after the last residue of
Cubl, as shown in Fig. 2E andF. These cleavages of bothDST-f1
andDST-f2 release the now-active (reconstituted) restrictase r1
from its association with human DNA and lead to r1-mediated
destruction of the DST vector (Fig. 2F). This vector encodes,
in particular, the DST-f1 and DST-f2 fusions and, in addition,
contains multiple cleavage sites, indicated by red asterisks in
Fig. 2C, for restrictases r1 and r2, whose cleavage specificities
are identical. The overall result of r1 activation (Fig. 2 E and F)
is the destruction of DST vector, and thus the prevention of
induction of its payload P under conditions in which the above
DST circuit had detected the presence of DNA-1. Fig. 2G
describes an identically designed pair of fusions, termedDST-f3
and DST-f4, that differ from the pair DST-f1/DST-f2 (Fig. 2 A,
B, and D) in containing a distinct pair of zinc fingers (ZF2–1
and ZF2–2) that recognize DNA-2, a segment of DNA whose
sequence differs from that of DNA-1 (Fig. 2 E–G). The
involvement of DNA-2 converts a DST circuit into a Boolean
OR gate in that a DST vector would be destroyed if just one of
two DNA segments, DNA-1 or DNA-2, is engaged by corre-
sponding DST fusions (Fig. 2 D–G). The DNA sequence-
enabled assembly of a split protein, a part of the above circuit
(Fig. 2 E and F), was described previously in a different
(unrelated to DST) context of reconstituting, through the
binding of ZF proteins to DNA, a split GFP protein (31, 47).
7. Fig. 2B depicts DST-f2, a fusion ‘‘complementary’’ to DST-f1.
The two fusions can interact as a result of specific binding of the
fusions’ ZF1–1 and ZF1–2 moieties to adjacent DNA se-
quences of DNA-1, as described above and in Fig. 2 E and F.
8. Fig. 2C describes the ORFs of the DST vector, which contains
at least five ORFs. The ORF(s) encoding ‘‘payload’’ P (e.g., a
conditionally toxic protein) is in yellow. See item 11 for a
description of the payload’s design and induction. The other
ORFs of the DST vector encode DST-f1 (Fig. 2A), DST-f2
(Fig. 2B), DST-f3, and DST-f4 (Fig. 2G). The latter pair of
ORFs is identical to the one encoding DST-f1 and DST-f2,
except for the following differences: ZF2–1 and ZF2–2 ZF
domains of DST-f3 and DST-f4 recognize 9-bp DNA se-
quences distinct from those recognized by ZF1–1 and ZF1–2
(Fig. 2 A and B); and the split restrictase r2 of DST-f3/DST-f4,
although of the same cleavage specificity as the restrictase r1,
cannot ‘‘cross-reconstitute’’ with it. Red asterisks denote the
cleavage site recognized by r1 and r2 that is present in multiple
copies in the DST vector’s DNA but is absent from human
DNA. The DST vector is delivered into cells as nonspecifically
as possible, either as a part of DNA viruses that are being
developed for use in gene therapy, including therapy of cancer,
or by any other route (e.g., a liposome–DNA complex) that
involves a nonreplicating delivery vector, minimizes immuno-
genicity of the procedure and maximizes its efficiency (48–52).
9. Fig. 2 E–G describes the operation of the DST circuit in a
normal (nontarget) cell. The latter is shown, without loss of
generality, to contain both DNA-1 and DNA-2. (It can also
contain just one of two DNA segments.) Upon expression by
DST vector of DST-f1 and DST-f2, their DNA-recognizing
domains ZF1–1 and ZF1–2 locate and bind to their adjacent
recognition sites on humanDNA-1. This double binding by ZF
domains of the two fusions brings their polypeptide chains
together and triggers reconstitution of both the restrictase r1,
the Ub moiety, and the Ubl moiety of DST-f1/DST-f2. Recon-
stitution of the Ub and Ubl moieties results in cleavages of
peptide bonds after the last residue of Cub in DST-f1 and after
the last residue of Cubl in DST-f2 (see item 6). Because of the
way in which Cub and Cubl are placed in DST-f1/DST-f2, these
cleavages liberate the active (reconstituted) restrictase r1 moi-
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ety. This nuclease becomes free to target its cleavage sites in the
DST vector, digesting it to small fragments (Fig. 2F) and
thereby irreversibly stopping the expression of its ORFs, in-
cluding, crucially, the (possibility of) expression of the vector’s
payload. Note that the payload’s expression had not been
induced as yet at this stage (see item 11).
10. Fig. 2G depicts the DNA sequence-directed association of the
other two fusions, DST-f3 and DST-f4, followed by reconsti-
tution of the split Ub moiety, the split Ubl moiety, and the split
restrictase r2. The latter has the same cleavage specificity as r1
but differs from r1 in being unable to cross-associate with the
halves of r1. Mechanistically, the association of DST-f3 and
DST-f4 is similar to the association of DST-f1 and DST-f2, but
the f3/f4 fusions recognize the presence of DNA-2, whereas
f1/f2 recognize the presence of DNA-1. Because just one of
these two association events (let alone both of them) would
suffice for the activation of a restrictase(s) and destruction of
DST vector (Fig. 2 E–G), any nontarget cell, i.e., a cell
containing at least one of two DNA segments, DNA-1 and/or
DNA-2, would be spared.
11. Fig. 2H summarizes events in a target cell (the one containing
both HD1 and HD2 deletions) that received DST vector.
Neither DNA-1 nor DNA-2 are present in such a cell, owing to
the deletions HD1 and HD2. As a result, the reconstitution of
r1 and/or r2 restrictases, which require the binding of ZF
domains ZF1–1/ZF1–2 to (nonexistent) DNA-1, and/or of
ZF2–1/ZF2–2 to (nonexistent) DNA-2, does not take place,
and the DST vector stays intact. After an (empirically opti-
mized) time delay, to allow DST circuits to search for DNA-1
and/or DNA-2, the expression of the vector’s payload P (Fig.
2C) can be activated. Although later versions of DST may
‘‘automate’’ the induction of payload P, by making that induc-
tion a part of additional (time-delay) circuit encoded by DST
vector, the delayed induction of payload P is ‘‘manual’’ in the
current design, i.e., it is controlled by experimenter. It is
possible that the P-induction step will stay manual in later
elaborations of DST as well, because it may be beneficial to
control the all-important step of payload’s activation from
‘‘outside,’’ e.g., through the administration, to a patient, of an
inducer of payload’s toxicity after the state of DST vector
(intact or destroyed) is verified by independent tests in at least
some cells of a patient.
If the aim, in the end, is to kill target cells, rather than, for
example, to induce their terminal differentiation, the range of
possible toxic proteins to serve as a payload of the DST vector is
quite broad and includes either bacterial or plant toxins, for
example, diphtheria toxin or ricin. A gene that encodes payload P
can be controlled, for example, by a nonleaky inducible promoter
that can be activated by a small-compound inducer, such as, for
instance, doxycycline or ecdysone (53, 54). If one wishes to inter-
pose yet another level of temporal control, so that payload P (Fig.
2C) is expressed as a conditionally toxic protein, the range of
current choices includes, for example, the herpes simplex virus
thymidine kinase (HSV-tk) in the presence of its substrate acyclovir
(55). Other options include, for instance, the use of small-
compounddimerizers (56, 57), inwhich case the payloadP (Fig. 2C)
can be expressed as a split (conditional) toxin, with domains that
bind to a cell-penetrating dimerizer, bringing the two halves of a
toxic protein together in the presence of dimerizer and thereby
making it possible to uncouple the induction of the payload’s
expression from the step of actually killing a target cell. Given
several realistic choices of both the DST payload and its mode of
activation, specific details of this last step (Fig. 2C andH) aremuch
less important at present than the nature of strict control over the
possibility of payload expression that stems from the ability of the
DST vector to self-destruct in response to entering a nontarget cell
(Fig. 2F).
As mentioned in foregoing descriptions, the delivery of DST
vector into cells can be nonspecific, because the selectivity of DST
is an intracellular effect. If an actual, working DST circuit can be
made as selective for target cells as the current designs suggest it
may be, it would be best to employ a nonspecific, high-efficiency
delivery, so that a sizable fraction of patient’s cells, without regard
to their nature, locations, or cell-cycle positions, receive a (tran-
sient) visit by DST vector in a given round of DST therapy. This
would maximize the probability of not missing any target cells,
irrespective of their heterogeneity in surface properties and other
traits. For a more compact summary of DST and its mode of
operation, see Fig. 3. Although fairly elaborate, the overall design
(Fig. 2) is within reach of modern construction and expression
routines.
Concluding Remarks
The DST strategy brings together both existing and new method-
ologies, such as the Ub fusion technique (22, 23); the split-Ub assay
(24); ZF DNA-recognizing proteins (43–45); restriction nucleases
that are derived either from engineered ZF proteins (37–41) or
from homing endonucleases (35, 36) and that are configured (in
DST designs) as split nucleases; DNA sequence-enabled assembly
of a split protein (31); a new arrangement of split Ub-type domains
in a polypeptide chain that enables a double proteolytic cleavage
once two chains associate in vivo; and a new feedback mechanism
that receives input from a circuit operating as a Boolean OR gate
and involves the activation of split nucleases, which destroy theDST
vector in normal (nontarget) cells (Figs. 1–3). A certainty that an
HD in a cancer cell will be present in that cell and its progeny for
as long as those cells endure may lead to a changed perspective on
the nature of curative therapies. In what follows, I shall assume, for
the sake of argument and without proof, that the DST strategy will
advance, one day, from a diagram in the present work to an
efficacious cancer therapy.
The above description of DST circuit emphasized its fundamen-
tals rather than its technical details. Therefore it may be helpful to
mention that reconstituted nucleases, which mediate the destruc-
tion of DST vector in nontarget cells (Fig. 2), can also be, for
example, split recombinases such as Cre of the phage P1. A
corresponding Cre-sensitive DST vector would contain multiple
copies of loxP, the target of Cre, or (for example) a silent,
loxP-containing, Cre-activated transcriptional promoter upstream
of a gene encoding an intact (nonsplit) homing endonuclease. In the
latter case, a DST vector would contain multiple cleavage sites for
the endonuclease. In addition, the junction between a ZF domain
and a split-Ub (or a split Ub-like) module in a DST fusion (Fig. 2)
can be designed to activate a ZF-linked cryptic degron upon the
fusion’s cleavage, resulting in a short-lived ZF and multiple cycles
of split-nuclease reconstitution on a single-copy DNA segment.
A DST system verifies the physical absence of a (homozygously)
deleted DNA. In doing so, this circuit operates as a Boolean OR
gate, erring on the side of caution: If the DST system (Figs. 2 and
3) appears to detect even one (of two or more) segment of DNA
that is supposed to be absent from a target cell, the DST vector’s
genome is designed to irreversibly self-destruct, and the cell is
spared. This happens before the cytotoxic step (the activation of the
vector’s payload) is even ‘‘considered’’ by a circuit. Depending on
the specifics of a DST regimen, such an extent of double-checking
may result, stochastically, in letting go of some target cells that
should have been destroyed. Note, however, that if the therapy’s
selectivity for target cells versus nontarget (normal) cells is high
enough, the resulting disappearance of side effects brings forth an
opportunity that other, less-selective therapies are less able to
afford: the option of repeated treatments. The nonreversion prop-
erty of homozygous deletions is synergistic with the possibility of
making the frequency of DST’s error (i.e., the error of killing
nontarget cells) arbitrarily low. As a result, a DST treatment can be
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administered repeatedly, with the usual concerns about side effects
or alterations of targets either diminished or nonexistent.
AlthoughHDs themselves would never be a reason for increased
resistance to treatment, other sources of ‘‘acquired’’ resistance
would be there, of course. However, they can be dealt with, because
repeated treatments would now be feasible. The current DST
strategy (Figs. 1–3) is based on macromolecular structures, and
requires that a vector encoding them enters cells. Thus, a resistance
to DST treatment can build up in ways that are similar to the routes
that increase resistance to other cancer therapies as well. For
example, if a DST vector is delivered into cells using a virus or a
liposome-encapsulated DNA, the changing genetic landscape of a
patient’s cancer (in part because previous rounds of DST therapy
eliminated a subset of cancer cells) may result in the remaining
cancer cells being more resistant to entry of DST’s carrier. A
remedy, given the possibility of repeatedDST treatments, would be
to retain the DST vector but to deliver it through a different virus
or modified liposomes. Strategies of this kind would also be
expected to deal with the problem of a patient’s immune responses
to a viral vector. A potentially more difficult problem is an immune
response to intracellular DST-specific proteins (Fig. 2). I mention
such problems but do not discuss them here, because they recur in
other protein-based anticancer therapies as well. One hopes that
continuing advances in modulating immunological circuits selec-
tively enough to reduce an undesirable response without shutting
off the immune system will eventually address this difficulty.
The flexibility of DST in regard to repeated treatments has yet
another advantage: it is unnecessary to focus on the same set of
homozygous deletions throughout a DST therapy. Although Fig. 1
depicts theHDsHD1 andHD2 as being on separate chromosomes,
this is not an actual constraint, because a set of relevant HDs can
be present, a priori, anywhere in the genome. Cancer-associated
HDs are presumed to form early in the process that led to a specific
cancer, in part because some HDs eliminate genes for tumor
suppressors. However, the known cancer-associated HDs (8–21)
were identified either in cell lines established from tumors or by
examining advanced cancers. Therefore it is still unclear whether a
given cancer-associatedHD is present in all cancer cells of a patient
or in a large subset of them. Because the choice of HD targets
remains flexible throughout DST therapy, the above (potential)
complication can be dealt with by altering, if necessary, a set of
targeted HDs. Apart from its therapeutic usefulness, such an
alterationmay also illuminate the temporal position of specificHDs
in the history of a cancer. For example, if a choice of specific HDs
as DST targets leads to eradication of cancer cells in a patient, this
result would suggest that the chosen HDs were present in the
earliest population of tumorigenic cells that gave rise to that cancer.
Although this work described DST ideas in the context of
homozygous deletions (Figs. 1–3), a DST-type strategy is also
relevant to any setting in which one wishes to distinguish amongst
sets of cells that contain or lack specific DNA sequences and to
target one or the other such set. Thus, cell populations with specific
missense mutations, chromosomal translocations, hemizygous de-
letions (as distinguished from HDs), and copy-number increases in
specific DNA regions (gene amplification) can also be a part of
DST-type strategies. A major difference between DST-relevant
homozygous deletions and other genetic alterations are both the
permanence of HDs and their ‘‘digital’’ (all-or-none) quality,
accentuated by relatively large sizes of cancer-associated HDs:
hence the focus on homozygous deletions.
It is commonly assumed that if a universally applicable, curative,
low-collateral-damage therapy of cancer is feasible at all, it would
be attained through the understanding of tumor suppressors,
oncoproteins, immune surveillance and their perturbations by
cancer-causing mutations. The understanding of cancer’s biology is
already quite advanced (1). It is unknown, at present, whether the
DST strategy will make the transition from a set of concepts to an
efficacious cancer therapy. If it ever does, it would be striking that
a curative treatment is unrelated to biological understanding of
cancer, apart from its DNA-deletion specifications.
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